70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

doi:10.1056/NEJMoa1602253

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

The New England journal of medicine - 25 Aug 2016

Cardoso Fatima, van't Veer Laura J, Bogaerts Jan, Slaets Leen, Viale Giuseppe, Delaloge Suzette, Pierga Jean-Yves, Brain Etienne, Causeret Sylvain, DeLorenzi Mauro, Glas Annuska M, Golfinopoulos Vassilis, Goulioti Theodora, Knox Susan, Matos Erika, Meulemans Bart, Neijenhuis Peter A, Nitz Ulrike, Passalacqua Rodolfo, Ravdin Peter, Rubio Isabel T, Saghatchian Mahasti, Smilde Tineke J, Sotiriou Christos, Stork Lisette, Straehle Carolyn, Thomas Geraldine, Thompson Alastair M, van der Hoeven Jacobus M, Vuylsteke Peter, Bernards René, Tryfonidis Konstantinos, Rutgers Emiel, Piccart Martine

Abstract excerpt

BACKGROUND: The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical-pathological criteria in selecting patients for adjuvant chemotherapy. METHODS: In this randomized, phase 3 study, we enrolled 6693 women...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Mastectomy

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Oligonucleotide Array Sequence Analysis

Share to Risk

Source

Open in PubMed

Identifiers

PMID: 27557300
DOI: 10.1056/NEJMoa1602253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.PMID 27557300Read ↗

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerSemantic proximity Read ↗

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity Read ↗

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity Read ↗

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read ↗

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.Semantic proximity Read ↗

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read ↗

Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity Read ↗

A breast cancer gene signature for indolent disease.Semantic proximity Read ↗

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.